the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

Clinical trial NCT07339540 · RECRUITING

Trial details

NCT number: NCT07339540
Sponsor: Tongji Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Recurrent or Refractory Systemic Lupus Erythematosus Recurrent or Refractory IgG4 Related Diseases Recurrent or Refractory Systemic Sclerosis Recurrent or Refractory Idiopathic Inflammatory Myopathy Recurrent or Refractory ANCA Associated Vasculitis

Start date: 2025-11-04
Primary completion: 2028-10-30
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.